A double-blind, randomized placebo-controlled trial studying Botulinum NeuroToxin treatment in jerky and tremulous functional movement disorders

The article, which was published in the Journal of Neurology Neurosurgery and Psychiatry, stresses that patients with chronic functional symptoms can improve, despite the fact that prognosis is considered poor.

In the study, the effects of Botulinum Neurotoxin (BoNT) treatment in patients with chronic functional jerky and tremulous movement disorders were studied in a randomized double-blinded placebo-controlled manner. It showed that BoNT is just as effective as placebo, since motor improvement was about 60% in both treatment arms. After the trial phase, all patients were treated with BoNT during a one year open-label follow-up, which showed that an additional 44% of patients improved.